证券之星消息，12月19日医疗器械板块较上一交易日上涨0.56%，康众医疗领涨。当日上证指数报收于 3890.45，上涨0.36%。深证成指报收于13140.22，上涨0.66%。医疗器械板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 688607 | 康众医疗 | 44.90 | 7.36% | 4.57万 | 2.00亿 | | 688193 | 仁度生物 | 50.40 | 6.78% | 1.69万 | 8522.77万 | | 688626 | 翔宇医疗 | 54.01 | 5.72% | 4.32万 | 2.27亿 | | 688393 | 安必平 | 24.95 | 5.63% | ﻛ 6.69万 | 1.68亿 | | 688301 | 奕瑞科技 | 106.66 | 5.02% | 3.48万 | 3.66亿 | | 920925 | 锦好医疗 | 30.50 | 4.10% | 1.49万 | 4475.34万 | | 688236 | 春立医疗 | 2 ...

早盘AI医疗概念震荡回升，华人健康涨近15%，此前鹭燕医药2连板，美年健康、安必平、成都先导、 塞力医疗跟涨。 ...

（文章来源：证券日报） 证券日报网讯 12月11日，安必平在互动平台回答投资者提问时表示，股票价格受宏观经济环境、市场 行情、板块热点等多种因素影响。公司始终坚持聚焦病理行业，多措并举抓好生产经营，保证信息披露 及时、准确，不断加强市值管理。 ...

Group 1 - The company, Nanjing Qianjing Venture Capital Partnership, held 1,677,265 shares of Guangzhou Anbiping Pharmaceutical Technology Co., Ltd., accounting for 1.79% of the total share capital before the reduction plan [1] - The reduction plan involved Nanjing Qianjing intending to reduce its holdings by up to 1,677,265 shares through centralized bidding and block trading, which represents 1.79% of the company's total share capital [1] - As of December 3, 2025, Nanjing Qianjing had reduced its holdings by 174,922 shares, which is 0.19% of the total share capital, and the reduction plan period has expired [1][3] Group 2 - The reduction subject has no concerted actions with other parties [2] - The actual reduction complied with relevant laws and regulations, and the actual reduction was consistent with the previously disclosed reduction plan [5] - The reduction plan was fully implemented, and there were no violations of the reduction plan or other commitments [5]

（编辑 袁冠琳） 证券日报网讯 12月3日晚间，安必平发布公告称，南京乾靖创业投资合伙企业（有限合伙）于2025年9 月4日至12月3日以集中竞价方式累计减持公司股票174，922股，减持比例占公司总股本0.19%，减持计 划时间区间已届满。 ...

证券代码：688393 证券简称：安必平 公告编号：2025-052 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 股东的基本情况 广州安必平医药科技股份有限公司 本次减持计划实施前，南京乾靖创业投资合伙企业（有限合伙）（以下简称 "南京乾靖"）持有广州安必平医药科技股份有限公司（以下简称"公司"） 1,677,265 股股份，占公司总股本的比例为 1.79%，该等股份为南京乾靖于公司 首次公开发行并上市前取得的股份，且已于 2021 年 8 月 20 日解除限售后上市流 通。 股东减持股份计划时间届满暨减持股份结果公告 减持计划的实施结果情况 2025 年 8 月 14 日，公司披露了《广州安必平医药科技股份有限公司股东减 持股份计划公告》（公告编号：2025-033），南京乾靖拟通过集中竞价方式及大 宗交易方式减持所持有的公司股份不超过 1,677,265 股(含本数)，不超过公司目 前总股本的 1.79%。 2025 年 12 月 3 日，公司收到股东南京乾靖发来的《关于股份减持的告知函 ...

格隆汇12月3日丨安必平(688393.SH)公布，2025年12月3日，公司收到股东南京乾靖发来的《关于股份 减持的告知函》,减持计划期间南京乾靖以集中竞价的方式累计减持公司股票17.49万股，减持比例占公 司总股本0.19%。本次减持计划时间区间已届满。 ...

Group 1 - Recent collaboration between Anbiping (688393.SH) and CSPC Pharmaceutical Group (1093.HK) focuses on the development of C-MET companion diagnostics [1] - Anbiping will be responsible for the development of immunohistochemistry companion diagnostic products and the commercialization of IVD/CDx kits, enhancing clinical applications for cancer patients [2] - CSPC Pharmaceutical Group, established in 1997, has maintained double-digit growth in key operational metrics and is recognized for its innovative development in the pharmaceutical industry [3] Group 2 - CSPC has two national key laboratories and over 60 products with annual sales exceeding 100 million, covering APIs, chemical drugs, biological drugs, and functional foods [3] - Anbiping, founded in 2005, is the first listed company in China focusing on pathology diagnostics, with over 200 self-developed immunohistochemistry antibodies and advanced digital + AI-assisted diagnostic products [4] - Anbiping serves over 3,000 medical institutions nationwide through its comprehensive business model that includes tumor screening, pathology diagnosis, smart pathology, and pathology services [4]

Fundraising Overview - The company has completed the fundraising project named "Pathological Digitalization and Intelligent Application Development Project" and has utilized the raised funds as planned, achieving the main research and development goals [1][3] - The remaining funds from the project amount to 303,200 yuan, which will be permanently used to supplement the company's working capital for daily operations [3] Regulatory Compliance - According to the regulations of the Shanghai Stock Exchange, if the remaining fundraising amount (including interest income) is below 10 million yuan, the company is exempt from board review procedures and does not require a clear opinion from the sponsor institution or independent financial advisor [2]

Group 1 - Yongtai Technology's wholly-owned subsidiary has received approval for trial production of a lithium battery additive project with an annual capacity of 5,000 tons, set to begin trial production [1] - Mengke Pharmaceutical has decided to terminate its plan to issue shares to a specific entity due to ongoing disagreements among major shareholders, which could impact the company's stable operations [1] - Anhui Construction's subsidiary has been approved to register and issue debt financing tools totaling 15 billion yuan, including 5 billion yuan in short-term financing notes and 10 billion yuan in medium-term notes [2] Group 2 - Koli'er plans to repurchase shares worth between 10 million and 20 million yuan, with a maximum repurchase price of 20.94 yuan per share, to implement an employee stock ownership plan [2] - Xinhua Pharmaceutical has received approval for the production of fumaric acid volnoral raw materials, which are used to treat gastroesophageal reflux disease [3] - Lianhuan Pharmaceutical has received approval for additional specifications of tadalafil tablets, expanding its product offerings for treating erectile dysfunction and benign prostatic hyperplasia [5] Group 3 - Greenland Holdings reported an increase of 1,834 lawsuits with a total amount of 6.587 billion yuan from October 21 to November 13, 2025 [7] - Lianke Technology plans to invest up to 600 million yuan of idle funds in low-risk financial products [8] - Yinglian Co. signed a strategic procurement contract for 5,000 million square meters of composite aluminum foil with a leading new energy technology company [10] Group 4 - China Eastern Airlines reported a 10.58% year-on-year increase in passenger turnover for October, with a capacity increase of 6.84% [12] - China National Airlines reported an 8.7% year-on-year increase in passenger turnover for October, with domestic and international capacity also showing growth [15] - Oupai Home plans to use 320 million yuan of idle funds to purchase structured deposits with expected annual yields between 0.65% and 2.50% [16] Group 5 - Tianwei Food has submitted H-share issuance application materials to the Hong Kong Stock Exchange, which have been accepted by the China Securities Regulatory Commission [18] - Guizhou Aviation plans to establish a subsidiary focused on the research, production, and market expansion of intelligent automotive components, with initial operating funds of 40 million yuan [20] - Daimai Co. plans to invest 100 million yuan to establish a wholly-owned subsidiary in Shanghai focused on robotics technology [22] Group 6 - Founder Securities has received approval to issue company bonds totaling up to 30 billion yuan [24] - Hengrui Medicine has received clinical trial approvals for multiple drugs, indicating ongoing research and development efforts [26] - Zhaojing Pharmaceutical's product ZG006 has received orphan drug designation from the FDA, providing various benefits for its development in the U.S. market [39]